NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback